ArticlesHereditary angioedema: a current state-of-the-art review, III: mechanisms of hereditary angioedema
Section snippets
INTRODUCTION
Although hereditary angioedema (HAE) was described earlier, its hereditary nature was first clearly recognized in 1888 by Sir William Osler,1 who also provided the first complete, detailed, clinical description of this autosomal-dominant inherited disease. The explanation for this inheritance pattern is that people with HAE are heterozygous for deficiency of C1 inhibitor (C1-INH). Donaldson and Evans2 were the first to recognize that C1-INH was deficient in the plasma of patients with HAE.
THE BIOLOGICAL FUNCTION OF C1-INH
C1-INH is the only serine protease inhibitor that plays a significant role in regulation of complement activation. It is the primary regulator of classic pathway activation via inactivation of C1r and C1s (Table 1).5 It also regulates lectin pathway activation via inactivation of a C1s-like protease known as mannan-binding lectin-associated protease 2 (MASP2), which is activated after binding of mannan-binding lectin to a microorganism surface.6 α2-Macroglobulin also is able to inactivate MASP2.
PATHOPHYSIOLOGIC CHARACTERISTICS OF ANGIOEDEMA ATTACKS
Attacks of angioedema in HAE are not associated with signs of inflammation, although attacks may be triggered by inflammatory conditions. There also is no indication that allergy plays a role. Although some reports initially suggested that histamine levels in the urine were elevated during HAE attacks, a later study10 demonstrated that urinary histamine levels are not elevated. Furthermore, antihistamines are ineffective. Epinephrine also is ineffective in HAE.
C1-INH is a member of the serpin
The Complement and Contact Systems in HAE Attacks
Both the complement and contact systems are activated during HAE attacks. Low plasma levels of C1-INH in HAE result in apparent spontaneous activation of the complement and contact systems. This clearly occurs during attacks of angioedema but may also take place at a low level during asymptomatic intervals. The most readily identifiable indication of contact system activation is the presence of circulating, cleaved, high-molecular-weight kininogen during episodes of angioedema.21 C2 and C4
CONCLUSIONS
The major biological roles of C1-INH relate to the regulation of vascular permeability and the modulation of inflammation. The C1-INH regulates activation of the complement and contact systems. Suppression of contact system activation by inactivation of plasma kallikrein and factor XIIa, which prevents bradykinin release, helps to maintain the endothelial barrier. The loss of this function is illustrated by the recurrent episodes of angioedema that develop in patients with HAE. As outlined in
REFERENCES (49)
- et al.
A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor C'1-esterase
Am J Med
(1963) - et al.
Hereditary angioneurotic edema, II: deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein
J Allergy
(1962) Mechanism of angioedema in first complement component inhibitor deficiency
Immunol Allergy Clin North Am
(2006)- et al.
Activation of the coagulation cascade in C1-inhibitor deficiencies
Blood
(1997) - et al.
Urine-histamine levels in patients with hereditary angioedema (HAE)
J Allergy Clin Immunol
(1988) Activation of plasminogen by human plasma kallikrein
Biochem Biophys Res Commun
(1969)- et al.
Activation of the first component of complement, C1: comparison of the effect of sixteen different enzymes on C1
Immunobiology
(1983) - et al.
Detection of in vitro and in vivo cleavage of high molecular weight kininogen in human plasma by immunoblotting with monoclonal antibodies
Blood
(1986) - et al.
Homozygous C3 deficiency: detection of C3 by radioimmunoassay
Clin Immunol Immunopathol
(1977) - et al.
Generation of bradykinin during incubation of hereditary angioedema plasma [abstract]
Mol Immunol
(1982)
Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of “spontaneous” formation of bradykinin
J Allergy Clin Immunol
Activation of factor XII and cleavage of high molecular weight kininogen during acute attacks in hereditary and acquired C1-inhibitor deficiencies
Immunopharmacology
Plasma bradykinin in angio-oedema
Lancet
Hereditary angio-neurotic oedema
Am J Med Sci
Some properties of an esterase derived from preparations of the first component of complement
J Exp Med
C1 inhibitor and hereditary angioneurotic edema
Annu Rev Immunol
On the role of C1-inhibitor as inhibitor of tissue-type plasminogen activator in human plasma
Thromb Haemost
Generation of plasmin during acute attacks of hereditary angioedema
J Lab Clin Med
The activation of plasminogen by Hageman factor (factor XII) and Hageman factor fragments
J Clin Invest
Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma
J Exp Med
A pre-albumin activator of prekallikrein
J Immunol
Activation of the classical pathway of complement by Hageman factor fragment
J Exp Med
Mechanisms of activation of C'1 esterase in hereditary angioneurotic edema plasma in vitro
J Exp Med
Angioedema during therapy with recombinant tissue plasminogen activator
Br J Haematol
Cited by (53)
Throat microbiota alterations in patients with hereditary angioedema
2022, World Allergy Organization JournalCitation Excerpt :Even among members of the same family with the same mutation, the frequency, location and severity of HAE attacks are highly variable.6,7 Some patients experience frequent life-threatening HAE episodes, while others experience only a mild course or even remain asymptomatic for life.8,9 The cause of clinical heterogeneity in HAE remains unclear.
Reviewing clinical considerations and guideline recommendations of C1 inhibitor prophylaxis for hereditary angioedema
2022, Clinical and Translational AllergyProphylaxis of acute attacks with a novel short-term protocol in Hereditary Angioedema patients requiring periodontal treatment
2020, Oral Health and Preventive DentistryThe skin in celiac disease patients: The other side of the coin
2019, Medicina (Lithuania)Angioedema: The etiology, epidemiology and classification of its clinical forms
2019, General MedicineHereditary angioedema: a Chinese perspective
2019, European Journal of Dermatology
Disclosure: The author has served as a consultant to each of the companies that are developing therapies for HAE: Jerini, Dyax, Lev Pharmaceuticals, Pharming, and CSL Behring.
Funding Sources: This study was supported by grants HD22082 and AI057366 from the National Institutes of Health.